LDN193189
Names | |
---|---|
Preferred IUPAC name
4-{6-[4-(Piperazin-1-yl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl}quinoline | |
Identifiers | |
CAS Number |
|
3D model (JSmol) |
|
PubChem CID |
|
UNII | |
CompTox Dashboard (EPA) |
|
InChI
| |
SMILES
| |
Properties | |
Chemical formula |
C25H22N6 |
Molar mass | 406.493 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
Infobox references | |
LDN193189 is a chemical compound used in the study of bone morphogenetic protein signalling through the ALK2, ALK3 and ALK6 receptors.[1] It has been researched for the treatment of fibrodysplasia ossificans progressiva.[2]
See also
References
- ↑ Cuny GD, Yu PB, Laha JK, Xing X, Liu JF, Lai CS, Deng DY, Sachidanandan C, Bloch KD, Peterson RT. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4388-92. doi:10.1016/j.bmcl.2008.06.052 PMID 18621530
- ↑ Williams E, Bullock AN. Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2. Bone. 2018 Apr;109:251-258. doi:10.1016/j.bone.2017.09.004 PMID 28918311
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.